Phathom Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Phathom Pharmaceuticals şirketinin kazançları yıllık ortalama -6.9% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 1.2% oranında artan oldu. Gelirler yıllık ortalama 104.4% oranında artan oldu.

Anahtar bilgiler

-6.9%

Kazanç büyüme oranı

33.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	6.0%
Gelir büyüme oranı	104.4%
Özkaynak getirisi	n/a
Net Marj	-1,292.1%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

Dec 11

Following Up On Phathom Pharmaceuticals

Sep 03

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Jun 26

Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorder

Nov 30

Gelir ve Gider Dağılımı

Phathom Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:PHAT Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	26	-339	271	39
30 Jun 24	10	-297	218	42
31 Mar 24	3	-247	161	48
31 Dec 23	1	-202	118	50
30 Sep 23	0	-177	92	52
30 Jun 23	0	-185	92	59
31 Mar 23	0	-195	99	65
31 Dec 22	0	-198	101	71
30 Sep 22	0	-179	90	69
30 Jun 22	0	-164	83	67
31 Mar 22	0	-150	70	69
31 Dec 21	0	-144	63	72
30 Sep 21	0	-162	54	100
30 Jun 21	0	-159	45	110
31 Mar 21	0	-144	36	103
31 Dec 20	0	-129	28	98
30 Sep 20	0	-173	20	69
30 Jun 20	0	-207	14	48
31 Mar 20	0	-274	11	36
31 Dec 19	0	-255	7	20
30 Sep 19	0	-158	4	8
30 Jun 19	0	-90	3	3
31 Mar 19	0	-2	2	0

Kaliteli Kazançlar: PHAT şu anda kârlı değil.

Büyüyen Kar Marjı: PHAT şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PHAT kârlı değildir ve zararlar son 5 yılda yılda 6.9% oranında artmıştır.

Büyüme Hızlandırma: PHAT 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: PHAT kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 54.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: PHAT 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/18 22:34
Gün Sonu Hisse Fiyatı	2024/12/18 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Phathom Pharmaceuticals, Inc. 11 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
null null	BMO Capital Markets Equity Research
Chase Knickerbocker	Craig-Hallum Capital Group LLC
Umer Raffat	Evercore ISI

Phathom Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Phathom Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Phathom Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Phathom Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Recent updates

Independent Director recently bought US$99k worth of stock

Phathom Pharmaceuticals, Inc. Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for Vquezna®? (vonoprazan) Tablets

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

Consensus revenue estimates increase by 16%

New minor risk - Share price stability

Price target increased by 9.6% to US$24.43

Phathom Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Following Up On Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $129.999992 million.

Phathom Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $129.999992 million.

Consensus EPS estimates fall by 14%, revenue upgraded

New minor risk - Profitability

Phathom Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

President recently sold US$397k worth of stock

Phathom Pharmaceuticals Announces FDA Approval of Vquezna®? (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GermanyD in Adults

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Consensus EPS estimates fall by 12%

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

President recently sold US$154k worth of stock

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

New minor risk - Profitability

Forecast to breakeven in 2026

Phathom Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Phathom Pharmaceuticals Announces Voquezna® (Vonoprazan) Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Consensus revenue estimates decrease by 45%

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

New minor risk - Share price stability

Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? (Vonoprazan) Tablets

New major risk - Negative shareholders equity

Independent Director recently bought US$59k worth of stock

Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany

Consensus EPS estimates upgraded to US$3.83 loss, revenue downgraded

New major risk - Financial position

Price target increased by 14% to US$18.67

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $130.71875 million.

Consensus EPS estimates upgraded to US$4.52 loss

President recently bought US$101k worth of stock

Consensus revenue estimates decrease by 66%, EPS upgraded

Price target decreased by 12% to US$18.20

Phathom Pharmaceuticals, Inc. Approves in the U.S. for the Treatment of H. Pylori Infection, and Its Pending New Drug Application (NDA) for Vonoprazan for the Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Phathom Pharmaceuticals, Inc. Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

Price target decreased to US$26.20

High number of new directors

Phathom Pharmaceuticals, Inc. Completes Patient Enrollment in Its Phalcon-Nerd Daily Dosing Phase 3 Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

Phathom Pharmaceuticals, Inc Appoints James Topper to its Board of Directors

Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Consensus forecasts updated

The Prognosis For Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of Vonoprazan NDA for Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. Presents Data on Novel Potassium-Competitive Acid Blocker Vonoprazan from Range of Studies at Digestive Disease Week 2022

Price target decreased to US$42.80

Co-Founder & COO recently bought US$163k worth of stock

Price target decreased to US$46.20

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

High number of new and inexperienced directors

Phathom Pharmaceuticals, Inc. Appoints Frank Karbe to its Board of Directors

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phathom Pharmaceuticals: Undiscovered Gem

Price target decreased to US$53.40

Forecast to breakeven in 2024

High number of new and inexperienced directors

Phathom Pharmaceuticals, Inc. Announces Results from VONO-103

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

Phathom Pharmaceuticals, Inc. Announces FDA Grants Additional QIDP Designations to Vonoprazan Triple Therapy and Vonoprazan Dual Therapy, Each Containing Amoxicillin Capsules, for the Treatment of H. Pylori Infection

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter Pylori (H. Pylori) Infection; Study Met All Primary and Secondary Endpoints

Phathom Pharmaceuticals, Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $94.5 million.